Literature DB >> 23897283

Paediatrics: Children need optimal management of chronic hepatitis B.

Mei-Hwei Chang1.   

Abstract

Current therapies for chronic HBV infection are focused on adults. However, the timing of primary infection of HBV often occurs during infancy or childhood, particularly in endemic areas. Children have the potential for a long lifespan and should be treated properly and early before complications develop.

Entities:  

Mesh：

Year:  2013        PMID： 23897283     DOI： 10.1038/nrgastro.2013.137

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


  10 in total

1.  Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition.

Authors:  Etienne M Sokal; Massimiliano Paganelli; Stefan Wirth; Piotr Socha; Pietro Vajro; Florence Lacaille; Deirdre Kelly; Giorgina Mieli-Vergani
Journal:  J Hepatol       Date:  2013-05-23       Impact factor: 25.083

2.  Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period: clinical and liver histologic studies.

Authors:  M H Chang; L Y Hwang; H C Hsu; C Y Lee; R P Beasley
Journal:  Hepatology       Date:  1988 Mar-Apr       Impact factor: 17.425

Review 3.  Emerging pipeline drugs for hepatitis B infection.

Authors:  Natravis Cox; Hans Tillmann
Journal:  Expert Opin Emerg Drugs       Date:  2011-12       Impact factor: 4.191

4.  Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV.

Authors:  Huey-Ling Chen; Lung-Huang Lin; Fu-Chang Hu; Jian-Te Lee; Wen-Terng Lin; Yao-Jung Yang; Fu-Chen Huang; Shu-Fen Wu; Solomon Chih-Cheng Chen; Wan-Hsin Wen; Chia-Hsiang Chu; Yen-Hsuan Ni; Hong-Yuan Hsu; Pei-Lin Tsai; Cheng-Lun Chiang; Ming-Kwang Shyu; Ping-Ing Lee; Feng-Yee Chang; Mei-Hwei Chang
Journal:  Gastroenterology       Date:  2011-12-23       Impact factor: 22.682

5.  The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway.

Authors:  Tali Lang; Camden Lo; Narelle Skinner; Stephen Locarnini; Kumar Visvanathan; Ashley Mansell
Journal:  J Hepatol       Date:  2011-02-18       Impact factor: 25.083

6.  Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion.

Authors:  Yen-Hsuan Ni; Mei-Hwei Chang; Pei-Jer Chen; Keh-Sung Tsai; Hong-Yuan Hsu; Huey-Ling Chen; Daw-Jen Tsuei; Ding-Shinn Chen
Journal:  Gastroenterology       Date:  2007-04-11       Impact factor: 22.682

7.  Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood.

Authors:  M H Chang; P J Chen; J Y Chen; M Y Lai; H C Hsu; D C Lian; Y G Liu; D S Chen
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

8.  Effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men.

Authors:  Jia-Feng Wu; Wen-Yu Tsai; Hong-Yuan Hsu; Yen-Hsuan Ni; Huey-Ling Chen; Daw-Jen Tsuei; Mei-Hwei Chang
Journal:  Gastroenterology       Date:  2009-12-04       Impact factor: 22.682

Review 9.  The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy.

Authors:  Jinhong Chang; Timothy M Block; Ju-Tao Guo
Journal:  Antiviral Res       Date:  2012-10-13       Impact factor: 5.970

10.  Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence.

Authors:  Angela J Frodsham; Lyna Zhang; Uga Dumpis; Nor Azizah Mohd Taib; Steve Best; Andrew Durham; Branwen J W Hennig; Simon Hellier; Susanne Knapp; Mark Wright; Maria Chiaramonte; John I Bell; Mary Graves; Hilton C Whittle; Howard C Thomas; Mark R Thursz; Adrian V S Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205
  10 in total
  1 in total

1.  Defective natural killer cell anti-viral capacity in paediatric HBV infection.

Authors:  I L Heiberg; L J Pallett; T N Winther; B Høgh; M K Maini; D Peppa
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.